PDE5A and basal cell carcinoma: Some reports have demonstrated that using PDE5 inhibitors may be associated with increased risk of melanoma and basal cell carcinoma [12,13,14] although several studies conclude the causal connections need solid evidence between using PDE5 inhibitors and risk of melanoma [15,16].